《MedRxiv,2月23日,Development and Evaluation of A CRISPR-based Diagnostic For 2019-novel Coronavirus》

  • 来源专题:COVID-19科研动态监测
  • 编译者: xuwenwhlib
  • 发布时间:2020-02-24
  • Development and Evaluation of A CRISPR-based Diagnostic For 2019-novel Coronavirus

    Tieying Hou, Weiqi Zeng, Minling Yang, Wenjing Chen, Lili Ren, Jingwen Ai, Ji Wu, Yalong Liao, Xuejing Gou, Yongjun Li, Xiaorui Wang, Hang Su, Jianwei Wang, Bing Gu, Teng Xu

    doi: https://doi.org/10.1101/2020.02.22.20025460

    Abstract

    Background: The recent outbreak of infections by the 2019 novel coronavirus (2019-nCoV), the third zoonotic CoV has raised great public health concern. The demand for rapid and accurate diagnosis of this novel pathogen brought significant clinical and technological challenges. Currently, metagenomic next-generation sequencing (mNGS) and reverse-transcription PCR (RT-PCR) are the most widely used molecular diagnostics. Methods: 2019-nCoV infections were confirmed in 52 specimens by mNGS. Genomic information was analyzed and used for the design and development of an isothermal, CRISPR-based diagnostic for this novel virus. The diagnostic performance of CRISPR-nCoV was assessed and compared across three technology platforms (mNGS, RT-PCR and CRISPR). Results: 2019-nCoVs sequenced in our study were conserved with the Wuhan strain, and shared certain genetic similarity with SARS-CoV. A high degree of variation in the level of viral RNA was observed in clinical specimens. CRISPR-nCoV demonstrated a near single-copy sensitivity and great clinical sensitivity with a shorter turn-around time than RT-PCR. Conclusion: CRISPR-nCoV presents as a promising diagnostic option for the emerging pathogen.

    *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用.

  • 原文来源:https://www.medrxiv.org/content/10.1101/2020.02.22.20025460v1
相关报告
  • 《MedRxiv,3月10日,Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a CRISPR-based DETECTR Lateral Flow Assay》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-03-11
    • Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a CRISPR-based DETECTR Lateral Flow Assay James P Broughton, Xianding Deng, Guixia Yu, Clare L Fasching, Jasmeet Singh, Jessica Streithorst, Andrea Granados, Alicia Sotomayor-Gonzalez, Kelsey Zorn, Allan Gopez, Elaine Hsu, Wei Gu, Steven Miller, Chao-Yang Pan, Hugo Guevara, Debra Wadford, Janice Chen, Charles Y Chiu doi: https://doi.org/10.1101/2020.03.06.20032334 Abstract An outbreak of novel betacoronavirus, SARS-CoV-2 (formerly named 2019-nCoV), began in Wuhan, China in December 2019 and the COVID-19 disease associated with infection has since spread rapidly to multiple countries. Here we report the development of SARS-CoV-2 DETECTR, a rapid (~30 min), low-cost, and accurate CRISPR-Cas12 based lateral flow assay for detection of SARS-CoV-2. We validated this method using contrived reference samples and clinical samples from infected US patients and demonstrated comparable performance to the US CDC SARS-CoV-2 real-time RT-PCR assay. *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用.
  • 《2月23日_基于CRISPR的2019-nCoV诊断方法的开发和评估》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-02-24
    • 1.时间:2020年2月23日 2.机构或团队:广东省人民医院、广州视觉医疗有限公司、复旦大学附属华山医院等 3.事件概要: 广东省人民医院等于2020年2月23日在medRxiv上发表题为“Development and Evaluation of A CRISPR-based Diagnostic For 2019-novel Coronavirus”的文章。 文章指出,近期爆发的2019年新型冠状病毒(2019-nCoV)疫情引起了公众极大的关注。人们对快速、准确诊断这种新型病原体的需求带来了重大的临床和技术挑战。基于宏基因组新一代测序技术(mNGS)和逆转录PCR(RT-PCR)是目前应用最广的分子诊断方法。研究人员利用mNGS确认了52个样本中的2019-nCoV感染,分析了基因组信息,并将其用于这种新型病毒基于CRISPR的等温诊断方法的设计和开发。研究人员利用三种技术平台(mNGS,RT-PCR和CRISPR)评估和比较了CRISPR-nCoV的诊断性能。结果显示,其研究中测序的2019-nCoVs与武汉出现的病毒株序列相似,并且与SARS-CoV有一定的遗传相似性。研究人员在临床样本中观察到病毒RNA水平的高度变化。 CRISPR-nCoV与RT-PCR相比,具有近乎单拷贝的敏感性和极高的临床敏感性,且周期较短。研究人员指出,CRISPR-nCoV可作为一种有前景的新兴病原体诊断选方法。 4.附件: 原文链接:https://www.medrxiv.org/content/10.1101/2020.02.22.20025460v1